The global dry eye disease market is estimated to be valued at USD 7.33 Bn in 2024 and is expected to exhibit a CAGR of 8.8% during the forecast period (2024-2031). Dry eye disease, also known as keratoconjunctivitis sicca, is a multifactorial disease of the tears and ocular surface that results in symptoms of discomfort, visual disturbance, and tear film instability with potential damage to the interpalpebral ocular surface. It is accompanied by increased osmolarity of the tear film and inflammation of the ocular surface. Dry eye disease is a growing problem worldwide due to aging populations and greater use of digital devices, leading to decreased blink rates and more time spent with eyes open. Although often thought of as a mild, nuisance disease, dry eye can negatively impact quality of life and productivity.

Market Dynamics:

The global dry eye disease market is driven by the rising geriatric population globally which is majorly affected by dry eye disease due to age-related decreasing tear production. Furthermore, increasing usage of digital devices, such as smartphones, laptops, and tablets, for extended periods are majorly straining eyes leading to dry eyes, thereby driving the market growth. However, lack of awareness about treatment options, self-care, and management of dry eye disease especially in developing nations act as major market restraints. Market participants have the chance to explore new avenues in product development, including innovative delivery methods for artificial tears and combination therapies aimed at addressing both the signs and symptoms of dry eye disease.

Key Features of the Study:

• This report provides an in-depth analysis of the global dry eye disease market, and provides market size (USD BN) and compound annual growth rate (CAGR%) for the forecast period (2024–2031), considering 2023 as the base year.
• It elucidates potential revenue growth opportunities across different segments and explains attractive investment proposition matrices for this market.
• This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players.
• It profiles key players in the global dry eye disease market based on the following parameters – company highlights, products portfolio, key highlights, financial performance, and strategies.
• Key companies covered as a part of this study includes Novartis AG, Alcon Inc., I-MED Pharma Inc, Sun Pharmaceutical Industries Ltd., Novaliq GmbH, Cipla Inc., AbbVie Inc., Lupin, Otsuka Holdings Co., Ltd., Santen Pharmaceutical Co., Ltd, Cambium Medical Technologies, Viatris Inc., Teva Pharmaceutical Industries Ltd., Bausch & Lomb Incorporated, Abbott, Adrif Vision, Grevis Pharmaceuticals Pvt. Ltd., AFT Pharmaceuticals, URSAPHARM Arzneimittel GmbH, and Altacor.
• Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics.
• The global dry eye disease market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts.
• Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global dry eye disease market.

Detailed Segmentation-

• Product Type:
  • Cyclosporine
  • Corticosteroids
  • Lifitegrast
  • Ocular Lubricant
  • Punctal Plugs
  • Others
• Formulation Type:
  • Liquid
  • Gel
  • Ointment
  • Others
• Distribution Channel:
  • Hospital Pharmacies
  • Retail Pharmacies
  • Supermarket/Hypermarket
  • Other Stores
  • Online Pharmacies
• Region:
  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East
  • Africa
• Company Profiles:
  • Novartis AG
  • Alcon Inc.
  • I-MED Pharma Inc
  • Sun Pharmaceutical Industries Ltd.
  • Novaliq GmbH
  • Cipla Inc.
  • AbbVie Inc.
  • Lupin
  • Otsuka Holdings Co., Ltd.
  • Santen Pharmaceutical Co., Ltd
  • Cambium Medical Technologies
  • Viatris Inc.
  • Teva Pharmaceutical Industries Ltd.
  • Bausch & Lomb Incorporated
  • Abbott
  • Adrif Vision
  • Grevis Pharmaceuticals Pvt. Ltd.
  • AFT Pharmaceuticals
  • URSAPHARM Arzneimittel GmbH
  • Altacor